Key result
Adjunctive minocycline did not improve functional independence at 3 months compared to placebo or standard care in patients with acute ischemic stroke.
Why the study?
Does adjunctive minocycline improve functional and neurological recovery in patients with acute ischemic stroke?
Meta-Analysis (n=2,197)
Does adjunctive minocycline improve functional and neurological recovery in patients with acute ischemic stroke?
Answers are grounded in this paper and cite their sources.
Adjunctive minocycline in acute ischemic stroke improves neurological impairment scores but does not significantly increase the rate of functional independence at 3 months.
Background Acute ischemic stroke (AIS) is a leading cause of mortality and long‐term disability worldwide. Despite advances in acute stroke management, many patients continue to experience substantial neurological disability and incomplete recovery. Minocycline, a tetracycline antibiotic with anti‐inflammatory and neuroprotective properties and good blood–brain barrier penetration, has been investigated as a potential adjunctive therapy in AIS. Methods A systematic search of major databases was conducted identifying randomized controlled trials evaluating minocycline in patients with AIS. Outcomes included functional and neurological recovery assessed using the modified Rankin Scale (mRS), National Institutes of Health Stroke Scale (NIHSS), and Barthel index (BI), as well as mortality and vascular events. Pooled effect estimates were calculated using random‐effects meta‐analysis. Results Seven RCTs comprising 2197 patients were included, with 1093 receiving minocycline and 1104 receiving placebo or standard care. Functional independence at 3 months (mRS 0–2) showed no significant difference between groups (RR 1.28, 95% CI 0.97–1.69; I 2 = 84.9%). Minocycline was associated with lower NIHSS scores (MD −2.45, 95% CI −4.32 to −0.59; I 2 = 88.6%) and higher BI scores (MD 12.52, 95% CI 6.28–18.76; I 2 = 47.0%). Mortality (RR 0.66, 95% CI 0.39–1.090 and stroke recurrence or MI showed no significant differences (RR 0.97, 95% CI 0.69–1.37). Conclusions Although a consistent improvement in functional independence was not demonstrated, minocycline showed signals of benefit in selected neurological outcomes with a favorable safety profile. These findings support the need for adequately powered, multicenter randomized trials to clarify its therapeutic role.
No takes yet. Share an insight, caveat, or question.
Khalid et al. (2026) conducted a meta-analysis in Acute ischemic stroke (AIS) (n=2,197). Minocycline vs. Placebo or standard care was evaluated on Functional independence at 3 months (mRS 0-2) (RR 1.28, 95% CI 0.97-1.69). Adjunctive minocycline did not improve functional independence at 3 months compared to placebo or standard care in patients with acute ischemic stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: